NCT01055756撤回3 期
Clinical Trial Of The Effectiveness Of The Product Cloratadd D (Loratadine + Pseudoephedrine Sulfate) Produced By The Laboratory EMS S/A, Compared To The Drug Claritin D Produced By Schering-Plough S/A, In Patients With Allergic Rhinitis
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- Clinical signs and symptoms and nasal flow
研究概览
简要总结
The primary objective of this study is to evaluate the clinical efficacy of the drug Cloratadd D ® (loratadine + pseudoephedrine sulfate - EMS S/A) compared to the drug Claritin D ® (loratadine + pseudoephedrine sulfate - Schering Plough) in patients with allergic rhinitis by quantification of the scores of clinical parameters (signs and symptoms) and laboratory (nasal flow) down through time.
详细描述
Secondly, it will be observed safety (tolerability) clinic after the administration of the drug in patients by comparing the clinical parameters and the incidence of adverse events.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Accept the Consent Form.
- •Age between 18 and 60 years, regardless of sex;
- •Agree to return to all evaluations of the study;
- •Presenting the allergic symptoms confirmed by physical examination and by laboratory tests (IgE and sensitivity to the mite Dermatophagoides pteronyssinus), which should provide a diagnosis of allergic rhinitis with mild to moderate.
排除标准
- •Have participated in any experimental study or have ingested any drug trial in the 12 months preceding the start of the study;
- •Made use of other medications that interfere with the regular response of the drug in the 4 weeks preceding the start of the study, such as steroids and antihistamines;
- •Be patient with sensitivity loratadine / pseudoephedrine sulfate;
- •Have any disease or anatomical abnormality in the upper airways is detrimental to the analysis of data, for example, tumors or septal deviations moderate and severe
- •Demonstrate a history of alcohol abuse, drugs or pharmaceuticals.
- •Have consumed alcohol within 48 hours prior to the period of hospitalization;
- •Have a history of liver disease or kidney disease;
- •Present framework of current asthma or recent (less than 1 year);
- •To present the severe pressure of any cause or be on medication for that;
- •Smokers or patients who stopped smoking less than 06 months;
- •Pregnant or nursing women;
- •Patients with heart disease or who use medication for the cardiovascular system that is suffering interference of the drugs studied, for example, β-blockers;
- •Patients using corticosteroids or other medicines that interact with the study drugs as monoamine oxidase;
- •Patients with a history of glaucoma, urinary retention, and hyperthyroidism;
- •Patients who have undergone facial plastic surgery that the physician's discretion, will interfere with nasal airflow
研究组 & 干预措施
Test (Cloratadd D)
Experimental
Loratadine + Pseudoephedrine sulfate Test
干预措施: Loratadine + Pseudoephedrine sulfate (Drug)
Comparator (Claritin D)
Active Comparator
Loratadine + Pseudoephedrine Comparator
干预措施: Loratadine + Pseudoephedrine sulfate (Drug)
结局指标
主要结局
Clinical signs and symptoms and nasal flow
时间窗: 12 hours.
次要结局
- Avaliation of Safety through the adverse affects observation(12 hours)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Ambroxol in New and Early DLB, A Phase IIa Multicentre Randomized Controlled Double Blind Clinical TrialDementia With Lewy BodiesNCT04588285Helse Fonna180
Unknown
3 期
Efficacy Maxinom® And Maxitrol® in Reducing The Signs And Symptoms Of Acute Bacterial ConjunctivitisAcuteBacterial ConjunctivitisNCT01227863Azidus Brasil70
已完成
3 期
Immunotherapy With Depigmented and Polymerized Allergen Extract of Olea Europaea (GPIT)RhinoconjunctivitisAllergyNCT00537342Laboratorios Leti, S.L.83
尚未招募
4 期
The Possible Efficacy and Protective Effect of Empagliflozin in Rheumatoid Arthritis Patients Treated with MethotrexateRheumatoid Arthritis (RA)Methotrexate Induced NephrotoxicityMethotrexate Adverse ReactionNCT06641128Tanta University44
已完成
3 期
A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes MellitusType 2 Diabetes MellitusNCT02597049Eli Lilly and Company424